Leukemia: Dendritic cell therapy shows promising effects to give in some leukemia patients with AML - Acute Myeloid Leukemia. Thus Belgian phase I / II trial in 10 patients. Article posted August 5, 2010
June 22, 2011: Please read the recently added information about Dr. Robert Gorter and Medical Center in Cologne this information: My experience with dr.Robert Gorter and the Medical Center Cologne. A warning
And click here for addresses of clinics in Germany, where dendritic cell therapy is given .
August 5, 2010: Source: Proc Natl Acad Sci U.S. A. July 14 2010.
Dendritic cell therapy seems in addition to chemotherapy for leukemia patients a potentially life-prolonging and perhaps even cure can be. This shows a phase I / II study with 10 patients with AML - Acute Myeloid Leukemia. In 2 patients brought about the dendritic cells, relies on its blood and associated with a Wilms' tumor gene (WT1) is known for its immunological activity, a partial remission in a complete remission. In one patient remained a complete remission achieved by chemotherapy now three years a complete remission without relapse. This news was presented in all major media in the UK but if you read the full study report shows that while it gives a promising result but not more than that. But read for yourself the complete study report button below the abstract:
Proc Natl Acad Sci U.S. A. July 14 2010. [Epub ahead of print]
Induction of complete and molecular remission in acute myeloid leukemia by Wilms' tumor 1 antigen dendritic cell-targeted vaccination.
Van Tendeloo VF , Van de Velde A , Van Driessche A , Cools N , S Anguille , Ladell K , Gostick E , Vermeulen K , Pieters K , Nijs G , Stein B , Smits EL , Schroyens WA , Gadisseur AP , I Vrelust , Jorens PG , Goossens H , de Vries IJ , Price DA , Oji Y , Oka Y , Sugiyama H , Berneman ZN .
University of Antwerp, Faculty of Medicine, Vaccine and Infectious Disease Institute (VAXINFECTIO) and Center for Cell Therapy and Regenerative Medicine, University Hospital Antwerp, Antwerp B-2650, Belgium.
Abstract
Active immunization Using tumor antigen-loaded dendritic cells holds promise for the adjuvant treatment of cancer to eradicate or control residual disease, but so far, most dendritic cell trials have ormed leg in end-stage Cancer Patients with high tumor loads. Here, in a phase I / II trial, we Investigated the effect of autologous dendritic cell vaccination in 10 patients with acute myeloid leukemia (AML). The Wilms' tumor 1 protein (WT1), a nearly universal tumor antigen, was Chosen as an immuno-therapeutic target Because of its role in leukemogenesis Established and superior immunogenic Characteristics. Two patients in partial remission after chemotherapy were complete remission Brought enter after intradermal administration of full-length WT1 mRNA-electroporated dendritic cells. In hypothesis two, and three other Patients Patients who were in complete remission, the AML-associated tumor markers returned to normal after dendritic cell vaccination, compatible with the induction of molecular remission. Clinical responses were correlated with vaccine-associated Increases in WT1-specific CD8 (+) T cell frequencies, as detected by peptide / HLA-A * 0201 tetramer staining, and elevated levels of activated natural killer cells postvaccination. Further More, vaccinated Patients showed Increased levels of WT1-specific IFN-gamma-producing CD8 (+) T cells and features of general immune activation. These data support the Further Development of vaccination with WT1 mRNA-loaded dendritic cells as a post-remission treatment to relapse in AML patients preventDefault full.
PMID: 20631300 [PubMed - as supplied by publisher]
